CSPC Pharmaceutical Group’s Stock Price Plummets by 14.08%, Trading at 4.88 HKD: A Sudden Market Shakeup

CSPC Pharmaceutical Group (1093)

4.88 HKD -0.80 (-14.08%) Volume: 353.77M

“CSPC Pharmaceutical Group’s stock price currently stands at 4.88 HKD, experiencing a significant drop of -14.08% this trading session with a trading volume of 353.77M. The stock has suffered a year-to-date (YTD) decline of -32.78%, reflecting a challenging period for the pharmaceutical giant.”

Latest developments on CSPC Pharmaceutical Group

Recently, CSPC Pharmaceutical Group Limited announced a steady growth in its operations, leading to shareholder rewards. The company declared an interim dividend of HKD 0.16 for the six months ended 30 June 2024, which is payable on 20 November 2024. Despite this positive news, CSPC Pharma’s stock price took a hit, collapsing by approximately 9% and hitting a new low in 5.5 years. This decline came as CCBI trimmed its target price to $8 while maintaining an outperform rating. The stock faded by over 4% as the interim underlying profit rose by 1.7% year over year, with further share buyback of up to $1 billion approved. These events have contributed to the fluctuations in CSPC Pharmaceutical Group‘s stock price movements today.

CSPC Pharmaceutical Group on Smartkarma

Analysts on Smartkarma, like Tina Banerjee, are bullish on CSPC Pharmaceutical Group (1093 HK) as the company reported steady growth in finished drugs in 2023, driven by new products like Mingfule, Yilouda, and Anfulike. CSPC plans to launch 50 innovative drugs in the next 5 years, aiming for continuous growth. With shares trading at a low P/E of 11.3x and a dividend yield of 4%+, the company is seen as a deep value high dividend yield idea with new launches expected to drive further growth.

In a research report titled “CSPC Pharmaceutical (1093 HK): Deep Value High Dividend Yield Idea; New Launches to Drive Growth” by Tina Banerjee on Smartkarma, analysts highlight the positive outlook for CSPC Pharmaceutical Group. The company’s focus on launching innovative drugs and common generics in the coming years is expected to provide momentum for growth. With the stock trading at attractive levels compared to peers and offering a high dividend yield, investors are optimistic about the potential for CSPC Pharmaceutical Group‘s future performance.

A look at CSPC Pharmaceutical Group Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

When looking at the long-term outlook for CSPC Pharmaceutical Group Limited, the company seems to be in a strong position based on the Smartkarma Smart Scores. With a high score in Dividend and Growth, investors can expect good returns and potential for growth in the future. Additionally, the company scores well in Resilience, indicating its ability to withstand market fluctuations and challenges. Although the Value and Momentum scores are not as high, the overall outlook for CSPC Pharmaceutical Group appears positive.

CSPC Pharmaceutical Group Limited is a company that manufactures and sells pharmaceutical products, including vitamin C, antibiotics, and common generic drugs. In addition to its current product offerings, the company is also involved in the development of innovative drugs and antibiotics. With strong scores in Dividend, Growth, and Resilience, CSPC Pharmaceutical Group seems to be well-positioned for long-term success in the pharmaceutical industry.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma